These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 10346718)

  • 41. [Patient education and specialty prescription information from the psychiatric viewpoint].
    Linden M
    Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):662-7; discussion 667-8. PubMed ID: 9527465
    [No Abstract]   [Full Text] [Related]  

  • 42. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 43. Risk management policy and black-box warnings: a qualitative analysis of US FDA proceedings.
    Cook DM; Gurugubelli RK; Bero LA
    Drug Saf; 2009; 32(11):1057-66. PubMed ID: 19810777
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The learned intermediary doctrine and patient package inserts: a balanced approach to preventing drug-related injury.
    Paytash CA
    Stanford Law Rev; 1999 May; 51(5):1343-71. PubMed ID: 10558426
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The influence of the drug legislation on drug information for the physician and patient].
    Schwabe U
    Internist (Berl); 1980 Jun; 21(6):311-7. PubMed ID: 7005167
    [No Abstract]   [Full Text] [Related]  

  • 46. What is prescription labeling communicating to doctors about hepatotoxic drugs? A study of FDA approved product labeling.
    Willy ME; Li Z
    Pharmacoepidemiol Drug Saf; 2004 Apr; 13(4):201-6. PubMed ID: 15255086
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Boxed warnings and other FDA communication tools.
    Marks NS; Weiss K
    Am Fam Physician; 2010 Feb; 81(3):259. PubMed ID: 20112882
    [No Abstract]   [Full Text] [Related]  

  • 48. Ethical and Practical Considerations in Removing Black Box Warnings from Drug Labels.
    Yeh JS; Sarpatwari A; Kesselheim AS
    Drug Saf; 2016 Aug; 39(8):709-14. PubMed ID: 27000800
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Legal issues concerning the promotion of pharmaceutical products on the internet to consumers.
    Reichertz PS
    Food Drug Law J; 1996; 51(3):355-65. PubMed ID: 11797712
    [No Abstract]   [Full Text] [Related]  

  • 50. Are drugs approved by the FDA safe and risk free?
    Natl Med Leg J; 1991; 2(1):8. PubMed ID: 2018814
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antidiarrheal drug products for over-the-counter human use; amendment of final monograph. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2004 May; 69(92):26301-2. PubMed ID: 15141675
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Response to comments on the proposed model of a professional drug label.
    Martinez MN; Brown SA; Copeland DD; Haibel GK; Koritz GD; Riddell MG; Riviere JE; Rollins LD
    J Am Vet Med Assoc; 1996 Dec; 209(12):2068-70. PubMed ID: 8960188
    [No Abstract]   [Full Text] [Related]  

  • 53. Communicating with patients about their medications.
    Kessler DA
    N Engl J Med; 1991 Dec; 325(23):1650-2. PubMed ID: 1944456
    [No Abstract]   [Full Text] [Related]  

  • 54. Prescription drugs, products liability, and preemption of tort litigation.
    DeAngelis CD; Fontanarosa PB
    JAMA; 2008 Oct; 300(16):1939-41. PubMed ID: 18940985
    [No Abstract]   [Full Text] [Related]  

  • 55. Proposed NSAID package insert labeling.
    Food and Drug Administration U.S. Public Health Service
    J Pain Palliat Care Pharmacother; 2006; 20(1):49-55. PubMed ID: 16687359
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sounding board. Creative tension: FDA and medicine.
    Kennedy D
    N Engl J Med; 1978 Apr; 298(15):846-50. PubMed ID: 345121
    [No Abstract]   [Full Text] [Related]  

  • 57. Information from your family doctor. Drug warnings: is my medicine safe?
    Am Fam Physician; 2010 Feb; 81(3):304. PubMed ID: 20128116
    [No Abstract]   [Full Text] [Related]  

  • 58. Extra-label rules: the final outcome.
    Curry-Galvin E
    J Am Vet Med Assoc; 1997 Jan; 210(1):10-2. PubMed ID: 8977639
    [No Abstract]   [Full Text] [Related]  

  • 59. AVMA legislation: partial solution to drug availability problem.
    Gloyd JS
    J Am Vet Med Assoc; 1993 Apr; 202(7):1055-6. PubMed ID: 8473213
    [No Abstract]   [Full Text] [Related]  

  • 60. Legal implications of preparing and dispensing approved drugs for unlabeled indications.
    Podell LB
    Am J Hosp Pharm; 1983 Jan; 40(1):111-3. PubMed ID: 6823981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.